MediciNova Inc. (MNOV)
1.91
0.00 (0.00%)
At close: Jan 15, 2025, 11:51 AM
undefined% (undefined)
| Bid | 1.88 |
| Market Cap | 93.68M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.21 |
| PE Ratio (ttm) | -9.1 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.92 |
| Volume | 14,149 |
| Avg. Volume (20D) | 77,345 |
| Open | 1.97 |
| Previous Close | 1.91 |
| Day's Range | 1.88 - 1.97 |
| 52-Week Range | 1.12 - 2.55 |
| Beta | undefined |
About MNOV
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced periphera...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 8, 2006
Employees 13
Stock Exchange NASDAQ
Ticker Symbol MNOV
Website https://www.medicinova.com
Analyst Forecast
According to 1 analyst ratings, the average rating for MNOV stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 371.20% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 month ago ·
Source
+14.98%
MediciNova shares are trading higher after D. Bora...
Unlock content with
Pro Subscription
2 months ago ·
Source
+49.02%
MediciNova shares are trading higher after the company announced that it was notified by Sanofi that the Sanofi/Novartis litigation was settled.
